L

Legend Biotech

Biotech & Life Sciences · Franklin Township, United States · Founded 2014 · IPO 2020

Legend Biotech is a biotechnology company that focuses on the development and commercialization of innovative cell therapies to treat serious and hard-to-treat diseases, including hematological malignancies and solid tumors. These are types of cancers that affect the blood, bone marrow, and lymph nodes, as well as solid masses of tissue. The company is technology agnostic, meaning it doesn't limit itself to one particular technology, but rather explores multiple technologies in its quest for effective treatments. The company operates in the global healthcare market, specifically in the sector of personalized medicine. Its business model involves the discovery, development, and commercialization of novel therapies. This means that Legend Biotech not only discovers and develops new treatments, but also takes them to market, selling them to healthcare providers and patients. Legend Biotech's revenue is generated through the licensing and sale of its therapies. For instance, it recently announced an exclusive global license agreement for certain CAR-T therapies. CAR-T therapy is a type of treatment that modifies a patient's own cells to fight cancer. The company also regularly communicates with investors, hosting conference calls to discuss financial results and business highlights. This indicates a commitment to transparency and investor relations. In summary, Legend Biotech is a comprehensive cell therapy company that uses innovative technologies to develop and commercialize treatments for serious and intractable diseases. Keywords: Biotechnology, Cell Therapy, Hematological Malignancies, Solid Tumors, Personalized Medicine, Discovery, Development, Commercialization, CAR-T Therapies, Investor Relations.